COVID-19 affects people differently. Sometimes it ravishes the immune system, and attacks the lungs, while other cases are asymptomatic and go unnoticed. A recent Newswire press release announced that a Utah-based biotechnology company called Inherent Biosciences received a grant to study epigenetic biomarkers to predict a patient response to COVID-19 infection. The $255,959 grant comes from the National Science Foundation in an effort to develop on-site clinical tests that screen incoming patients and prioritizes hospital resources based on the predicted infection severity.
NSF Granted $256K to Predict Severity of COVID Infections
The goal is to prioritize patients coming into the ER to ensure hospital resources are allocated efficiently.
Sep 15, 2020
Recommended
Recommended
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
